HPRA Drug Safety Newsletter Edition 96
Download:
hpra-drug-safety-newsletter-edition-96.pdf
326 KB
The latest edition of the HPRA Drug Safety Newsletter (DSN) includes important updates to support the safe and appropriate use of the following medicines:
Ulipristal acetate 5mg (Esmya) for uterine fibroids – suspension of marketing authorisation during ongoing review of liver injury risk
Paracetamol – reminder to prescribers on risk of hepatotoxicity in patients with risk factors
Durvalumab (Imfinzi▼) – risk of myasthenia gravis
Rivaroxaban (Xarelto) – not for use as thromboprophylaxis in patients who have recently undergone transcatheter aortic valve replacement
Selective Serotonin Reuptake Inhibitors (SSRI) and Serotonin-norepinephrine reuptake inhibitors (SNRI) – persistent sexual dysfunction after drug withdrawal
« Back